Search

Your search keyword '"Chan, Oscar Siu Hong"' showing total 9 results
Start Over Author "Chan, Oscar Siu Hong"
9 results on '"Chan, Oscar Siu Hong"'

1. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Author

Ahn, Myung-Ju, Mendoza, Marvin Jonne L., Pavlakis, Nick, Kato, Terufumi, Soo, Ross A., Kim, Dong-Wan, Liam, Chong Kin, Hsia, Te-Chun, Lee, Chee Khoon, Reungwetwattana, Thanyanan, Geater, Sarayut, Chan, Oscar Siu Hong, Prasongsook, Naiyarat, Solomon, Benjamin J., Nguyen, Thi Thai Hoa, Kozuki, Toshiyuki, Yang, James Chih-Hsin, Wu, Yi-Long, Mok, Tony Shu Kam, Tan, Daniel Shao-Weng, and Yatabe, Yasushi

Published
2022
Full Text
View/download PDF

2. Consensus Statements on Precision Oncology in the China Greater Bay Area

Author

Lam, Tai-Chung, Cho, William Chi-Shing, Au, Joseph Siu-Kie, Ma, Edmond Shiu-Kwan, Lam, Stephen Tak-Sum, Loong, Herbert Ho-Fung, Wong, Jason Wing Hon, Wong, S.N. Michael, Lee, Victor Ho-Fun, Leung, Roland Ching-Yu, Lau, Johnny Kin-Sang, Kam, Michael Tsz-Yeung, Mok, Florence Siu-Ting, Lim, Fiona Mei-Ying, Nyaw, Jonathan Shi-Feng, Tin, Winnie Wing-Yan, Cheung, Ka-Man, Chan, Oscar Siu-Hong, Kwong, Philip Wai-Kay, Cheung, Foon-Yiu, Poon, Darren M.C., Chik, Jeannie Yin-Kwan, Lam, Martin Ho-Ching, Chan, Lawrence Wing-Chi, Wong, Sze-Chuen Cesar, Cao, Ya-Bing, Hui, Cheng-Vai, Chen, Jack Zhi-Jian, Chang, Jian-Hua, Kong, Spring Feng-Ming, and El Helali, Aya

Published
2023
Full Text
View/download PDF

8. Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.

Author

Le, Xiuning, Eisert, Anna, Hsia, Te-Chun, Raut, Nirmal Vivek, Ahmad, Azura, Chan, Oscar Siu Hong, De Bondt, Charlotte, Farrugia, David, Froesch, Patrizia, González-Cao, Maria, Hendriks, Lizza, Hochmair, Maximilian J., Mazieres, Julien, O'Sullivan, Hazel, Samol, Jens, van der Wekken, Anthonie J., Yang, Tsung-Ying, Joshi, Kirti, Vlassak, Soetkin, and Chang, Gee-Chen

Published
2023
Full Text
View/download PDF

9. Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.

Author

Oscar Siu Hong Chan, Kowanetz, Marcin, Wai Tong Ng, Koeppen, Hartmut, Lai Kwan Chan, Rebecca Mei Wan Yeung, Haiyan Wu, Amler, Lukas, Mancao, Christoph, Chan, Oscar Siu Hong, Ng, Wai Tong, Chan, Lai Kwan, Yeung, Rebecca Mei Wan, and Wu, Haiyan

Subjects
*NASOPHARYNGITIS, *NASOPHARYNGOSCOPY, *CANCER, *IMMUNOTHERAPY, *TUMORS
Abstract

Objectives: Locally recurrent or metastatic nasopharyngeal cancer (NPC) remains an important challenge, with more effective and durable therapeutic options needed. Cancer immunotherapy, and in particular therapies that target the PD-L1/PD-1 immune checkpoint pathway, may provide new options to treat NPC patients. This study evaluated PD-L1 and CD8 expression levels and the respective associations with clinical and histopathological characteristics of patients with NPC.Materials and Methods: Diagnostic tumour biopsies were obtained before radical radiotherapy with or without chemotherapy from 161 patients with NPC. These biopsies were analysed for PD-L1 expression levels on tumour cells (TC) and tumour-infiltrating immune cells (IC), and for CD8 T-cell infiltration. Results were correlated with baseline characteristics and clinical outcomes with standard-of-care treatment regimens. Additionally, pre- and post-treatment-paired tumour samples were analysed (n=146).Results: 75% of tumours expressed PD-L1 on IC and 24% on TC. Baseline clinical characteristics of stage, sex and age did not correlate with PD-L1 expression. Additionally, overall survival and progression-free survival of standard-of-care treatment did not correlate with baseline PD-L1 expression. CD8 levels did correlate with clinical outcomes; however, results were confounded by other baseline characteristics. After treatment, PD-L1 expression dropped a median of 1.5% on IC and a median of 2.75% on TC. Median CD8 expression dropped 1.9%.Conclusions: Majority of NPC biopsy samples demonstrated PD-L1 expression on ⩾1% of IC, with fewer expressing PD-L1 on TC. In contrast to previous smaller studies, no prognostic value was observed for PD-L1 expression levels in patients with NPC. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results